Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Study Overview: Bristol-Myers Squibb, in collaboration with Janssen Research & Development, is conducting a Phase 3 study titled ‘A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome.’ The study aims to evaluate the efficacy and safety of Milvexian, an oral Factor XIa inhibitor, in reducing major adverse cardiovascular events such as cardiovascular death, myocardial infarction, and ischemic stroke, compared to a placebo.
Intervention/Treatment: The study tests Milvexian, administered orally at 25 mg twice daily, against a placebo. The treatment is intended to improve outcomes for patients who have recently experienced an acute coronary syndrome.
Study Design: This is a randomized, double-blind, placebo-controlled study with a parallel intervention model. It employs quadruple masking, meaning participants, care providers, investigators, and outcomes assessors are blinded. The primary purpose is treatment-focused.
Study Timeline: The study began on April 7, 2023, with its last update submitted on July 17, 2025. These dates are critical as they mark the study’s progression and updates, indicating ongoing recruitment and data collection.
Market Implications: The study’s progress could influence Bristol-Myers Squibb’s stock performance and investor sentiment, especially if Milvexian demonstrates significant benefits over existing treatments. Success in this study could position the company favorably against competitors in the cardiovascular treatment market.
Closing Sentence: The study is currently recruiting, with further details available on the ClinicalTrials portal.